Coherus Biosciences | CHRS - Operating Expenses

Stock Price
1.61
Daily Change
-0.40 -19.90%
Monthly
0.63%
Yearly
36.44%
Q1 Forecast
2.39

Coherus Biosciences reported $53.03M in Operating Expenses for its fiscal quarter ending in March of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Acadia Pharmaceuticals USD 242.88M 10.68M Sep/2025
Akebia Therapeutics USD 43.82M 16.98M Mar/2025
ALKERMES USD 1.73B 1.44B Sep/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Amarin USD 51.37M 14.6M Sep/2025
Amgen USD 5.9B 773M Dec/2025
Baxter International USD 3.19B 554.4M Dec/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 807.82M 259.3M Sep/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Coherus Biosciences USD 53.03M 43.41M Mar/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Fujifilm JPY 767.39B 27.7B Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
Merck USD 10.16B 558M Dec/2025
Myriad Genetics USD 229M 3.4M Sep/2025
Pacira USD 166.36M 4.5M Sep/2025
Perrigo USD 949.9M 50.8M Sep/2025
Pfizer USD 12.91B 79.89B Dec/2025
PTC Therapeutics USD 207.52M 6.21M Sep/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Sarepta Therapeutics USD 462.23M 33.28M Sep/2025
Teva Pharmaceutical Industries USD 4.22B 812M Dec/2025
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025
Xencor USD 68.52M 8.26M Sep/2025
Zoetis USD 1.55B 3.85B Dec/2025